Overview of essential tremor by Zesiewicz, Theresa A et al.
© 2010 Zesiewicz et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Neuropsychiatric Disease and Treatment 2010:6 401–408
Neuropsychiatric Disease and Treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
401
Review
open access to scientific and medical research
Open Access Full Text Article
4795
Overview of essential tremor
Theresa A Zesiewicz 
Abinaya Chari 
israt Jahan  
Amber M Miller 
Kelly L Sullivan
Department of Neurology,
Parkinson Research Foundation,
James A. Haley veterans 
Administration Hospital,
University of South Florida, Tampa, 
FL, USA
Correspondence: Theresa A Zesiewicz
Department of Neurology, University  
of South Florida, 12901 Bruce B Downs 
Boulevard, Tampa, FL 33612, USA
Tel 813-974-5909
Fax 813-974-8032
email tzesiewi@health.usf.edu
Abstract: Essential tremor (ET) is one of the most common movement disorders in the world. 
Despite this, only one medication (propranolol) is approved by the Food and Drug Administra-
tion (FDA) to treat it. Fortunately, recent studies have identified some additional medications as 
treatment of ET. Surgical procedures, such as deep brain stimulation of the ventral intermediate 
nucleus of the thalamus, offer treatment for refractory tremor. The epidemiology, pathogenesis, 
and medical and surgical treatment of ET will be discussed in this paper.
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Introduction
Essential tremor (ET) is one of the most common tremor disorders in the world, and 
is characterized by a postural and/or kinetic tremor. While the disease is often called 
“benign”, it frequently causes difficulty with everyday tasks such as writing, pour-
ing, and eating. Despite its high prevalence, only one medication (propranolol) is 
currently approved by the United States Food and Drug Administration (FDA) for its 
treatment.1 The last decade has witnessed advances in ET, including the finding that 
“nonmotor symptoms”, including mood and cognitive dysfunction, appear to occur 
more commonly in ET patients than in normal controls.2,3 Additional medications to 
primidone and propranolol have been identified that may effectively reduce tremor. 
This review will focus on the epidemiology, pathogenesis, and current medical and 
surgical therapy of ET.
Epidemiology
ET is more prevalent than Parkinson’s disease (PD) or Alzheimer disease (AD), 
and there is no world population that is immune to its development.4 The age- and 
gender-adjusted prevalence of ET is estimated to be 3 to 4 per 1000, with an annual 
incidence of 23.7 per 100,000.5 The incidence of ET rises with increasing age,4 
although the disease can also affect children.6 Approximately 4% of adults 40 years 
of age and older are affected by ET. A family history of ET appears to correlate with 
younger reported age of tremor onset.7 While there is no conclusive evidence that ET 
increases an individual’s risk of mortality, one longitudinal prospective study found 
a small increased risk of death in ET patients.8 However, further research is needed 
to corroborate this finding.
While ET has been thought to have a bimodal age of onset (young adulthood and 
middle age),9 one study of ET epidemiology that took place in both a population-based Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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practice and tertiary referral center found a bimodal distribu-
tion only in the latter.10 It is possible that young patients with 
ET may more likely be referred to a tertiary referral center.
Clinical characteristics of ET
ET is considered to be heterogeneous condition with variable 
clinical expression in affected patients. It is characterized by 
a postural and/or kinetic tremor in the frequency range of 
4 to 12 Hz. Tremor frequency generally decreases over time, 
while amplitude slowly increases. Alcohol transiently dimin-
ishes tremor amplitude in 50% to 90% of cases, although this 
may worsen after the effect of alcohol has worn off.
The location and amplitude of tremor in ET patients 
varies among patients. Approximately 90% of patients have 
tremor in their upper extremities, 30% have a head tremor, 
20% have a voice tremor, 10% have a face or jaw tremor, 
and 10% of ET patients may have a lower limb tremor.11 
  Isolated head tremor is generally considered part of the 
clinical spectrum of ET. At least 50% of ET patients have 
tandem gait abnormalities.12
Recent studies have uncovered the presence on “nonmotor 
symptoms” including mild cognitive changes,13 depression, 
anxiety, social phobias, olfactory and hearing deficits that 
occur more frequently in ET patients than in normal age-
matched controls.
Diagnosis of eT
ET is a clinical diagnosis, and there are currently no lab tests 
or radiological scans to aid in the diagnosis. Unfortunately, 
it is estimated that ET is misdiagnosed in 30% to 50% of 
cases.14,15 The consensus statement of the Movement Disorder 
Society on tremor includes the following clinical criteria for 
the diagnosis of ET.16
inclusion criteria
1.  Bilateral postural tremor with or without kinetic tremor, 
involving hands and forearms, that is visible and 
persistent
2.  Duration greater than 5 years
exclusion criteria
1.  Other abnormal neurological signs (except Froment’s 
sign)
2.  Presence of known causes of increased physiological 
tremor
3.  Concurrent or recent exposure to tremorogenic drugs or 
the presence of a drug withdrawal state
4.  Direct or indirect trauma to the nervous system within 
3 months before the onset of tremor
5.  Historical or clinical evidence of psychogenic origins
6.  Convincing evidence of sudden onset or evidence of 
stepwise deterioration
Deuschl and Elble proposed the following definition of 
three ET subtypes:17
1.  Hereditary ET, for patients who fulfill consensus criteria 
for definite or classic ET and also have a family of at least 
one affected relative in the immediate family. The onset 
of tremor in the patient and the family member must occur 
prior to age 65 years.
2.  Sporadic ET, for patients who fulfill the consensus criteria 
for definite or classic ET, but do not have an immediate 
family member with ET, and whose age at onset of ET 
is younger than 65 years.
3.  Senile ET, for patients who have definite or classic ET 
according to consensus criteria, but who develop ET at 
or after the age of 65 years. Patients may or may not have 
a family history of ET.
Another set of criteria for the diagnosis of ET may be 
found in the “The Washington Heights Inwood Genetic Study 
of Essential Tremor”.18 These criteria include:
1.  On examination, a +2 postural tremor* in at least one arm 
(a head tremor might also be present, but is not sufficient 
for the diagnosis)
2.  On examination, there must be a +2 kinetic tremor dur-
ing at least four tasks, or a +2 kinetic tremor on one task 
and a +3 kinetic tremor on a second task. Tasks include 
pouring water, using a spoon to drink water, drinking 
water, finger-to-nose maneuver, and drawing spirals
3.  If on examination the tremor is present in the dominant 
hand, then by report it must interfere with at least one 
activity of daily living (eating, drinking, writing or using 
the hands). If on examination the tremor is not present in 
the dominant hand, then this criterion is irrelevant
4.  Medications, hyperthyroidism, ethanol, and dystonia are 
not potential etiological factors
5.  Symptoms are not psychogenic (eg, bizarre features, fea-
tures inconsistent in character, the patient is distractable, 
or other psychiatric features on examination)
For these criteria, the following scale is used:
0 –  No visible tremor
1 –  Tremor is of low amplitude, barely perceivable, or 
intermittent
2 –  Tremor is of moderate amplitude (1–2 cm) and usu-
ally present, and is clearly oscillatoryNeuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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3 –  Tremor is of large amplitude (.2 cm), violent, and 
jerky, resulting in difficulty completing the task 
because of spilling or inability to hold a pen to paper.
Tremor rating scales (TRS) are used to evaluate ET, 
particularly in clinical trials. A commonly used TRS is 
the Fahn–Tolosa–Marin rating scale,19 which is completed 
by health care providers. The FTM rating scale evaluates 
ET based on its appearance, tasks such as drawing lines, 
spirals, and pouring liquids, and effect on activities or 
daily living. Elble et al found that a 1-point change in 
TRS represents a substantial change in tremor amplitude 
in ET patients.20
Gironell et al evaluated the diagnostic potential of neu-
rophysiologic analysis of tremor.21 Subjects included three 
hundred outpatients with postural tremor. Following the first 
clinic visit, accelerometry and surface electromyography was 
conducted, and patients were clinically diagnosed by two 
neurologists who were blinded to the results of neurophysi-
olgoical testing. Neurophysiologic criteria for the diagnosis 
of ET required the presence of all of the following:
1.  Rhythmic burst of postural tremor on EMG
2.  Tremor frequency greater than or equal to 4 Hz
3.  Absence of rest tremor or, if present, frequency 1.5 Hz 
lower than the postural tremor
4.  Absence of tremor latency from rest to postural 
position
5.  Changes of the dominant frequency peak less or equal to 
1 Hz after the weight load test
6.  No  changes  in  tremor  amplitude  after  mental 
concentration.
The neurophysiologic criteria for ET showed a   sensitivity 
of 98%, a specificity of 82%, a positive predictive value of 
95%, a negative predictive value of 91%, and positive prob-
ability ratio of 5.5.
Genetics
ET is commonly inherited by autosomal dominant trans-
mission with incomplete penetrance. In some families, 
transmission appears to be polygenic.22 Identified suscepti-
bility loci for ET include 3q13.1,23 2p22-p25,24 and 6p23.25 
Approximately 50% of ET patients have an affected first-
degree relative,11 and first-degree relatives of ET patients 
also appear to be five times more likely to develop ET than 
control subjects.26 A family history of ET appears to correlate 
with younger reported age of tremor onset. Not all cases of 
ET have a genetic etiology, however, and the disease may 
occur sporadically.27
Pathogenesis
The exact pathogenesis of ET is unknown. The disease may 
be caused by a central oscillator originating in the Guillain 
Mollaret triangle located in the brainstem. Other areas of 
the brain that have been implicated in the pathogenesis of 
ET are the inferior olivary nucleus and the cerebellum.28 
Evidence for cerebellar involvement includes the presence 
of “torpedos” or axonal swellings that have been identified 
in the Purkinje cells in some ET patients.29 One study also 
found a greater loss of Pukinje cells in the cerebellum of ET 
patients compared to normal controls.30
Whether ET is a neurodegenerative disorder or a non-
degenerative disease remains controversial. The finding of 
Lewy body pathology in some ET patients and Purkinje cell 
loss in others points towards a neurodegenerative process. 
However, ET may be caused by abnormal oscillatory dys-
function of the motor system, suggesting that it is not a pri-
mary neurodegenerative disease, but one in which there may 
be secondary neuronal damage as the disease   progresses.17 
Increased membrane excitability in motor circuits may play 
a key role in the pathogenesis of ET.31
Several studies suggest that there may be a link between 
PD and ET, although this remains controversial. For 
example, one prospective study of patients with ET found a 
fourfold increase in the risk of developing PD compared to 
individuals without ET.2 Rest tremor, which is commonly 
found in PD patients, also appears to occur in a subset of 
ET patients, for reasons that are unknown. Another study 
compared 53 patients with combined ET and PD to patients 
with diagnoses of either PD or ET alone,33 and found that 
the gender distribution of patients with a combination of ET 
and PD (67.9% male) was identical to that of PD patients 
(67.9% male) but different from that of ET patients (50.0% 
male) (P = 0.02).
Treatment of ET 
(pharmacotherapy)
Pharmacologic treatment of ET should be considered when 
tremor interferes with activities of daily living. Proper treatment 
is contingent on a correct diagnosis, and other possible causes 
of tremor must be excluded. Patients need to be informed that 
treatment of ET does not cure the disease, but may offer tremor 
improvement. Medications that are used to treat ET are those that 
are used to treat other medical conditions, such as hypertension 
and seizures. It is estimated that medications improve tremor 
magnitude in ET by about 50%. Unfortunately, 30% to 50% of 
ET patients will not respond to medical therapy.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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First-line pharmacologic agents used to treat ET are pro-
pranolol and primidone, although other medications including 
sotalol, atenolol, alprazolam, and topiramate have also been 
shown to provide tremor reduction.34 In cases of refractory 
tremor, a reversible, surgical procedure called deep brain 
stimulation (DBS) into the thalamus may effectively treat 
tremor.
Antihypertensive medications
Beta blockers and calcium channel blockers are medications 
that are commonly used to treat hypertension and other 
cardiovascular conditions. Propranolol (Inderal) is a nonse-
lective beta-adrenergic receptor antagonist that effectively 
treats tremor and is the only medication that is FDA-approved 
for the treatment of ET. The mean dose of propranolol in 
published, controlled trials was 185.2 mg/day. Propranolol 
is also available as a long-acting (LA) preparation with once 
daily dosing. Although this preparation has not been studied 
as extensively as the immediate formulation, evidence from 
two clinical studies suggests that it reduces tremor in patients 
with ET.35,36
Other antihypertensive medications, including atenolol 
(Tenormin) and sotalol (Sotacor) have been shown to reduce 
ET compared to placebo.37,38 One study compared atenolol 
to other beta blockers (sotalol and propranolol) and found 
that atenolol had a lower magnitude of effect than either 
of the other agents.37 There is also limited evidence that 
nadolol   (corgard) and nimodipine (nimotop) may treat ET.39,40 
One study of nadolol compared tremor responders to non-
  responders and observed that only patients who previously 
responded to propranolol experienced significant tremor 
reduction from nadalol.39 Verapamil (Calan) and nifedipine 
(Adalat) have not been shown to reduce tremor in controlled 
studies.41 Studies of clonidine (Catapress), flunarizine 
(Sibelium), metoprolol (Lopressor/Toprol), and nicardipine 
(Cardene) were either limited or produced conflicting results, 
and their potential use in treating tremor remains uncertain.
Antiepileptics
Primidone (Mysoline) is an anticonvulsant that effectively 
treats ET. Studies using accelerometry and clinical rating 
scales have demonstrated approximately a 50% reduction 
in tremor magnitude with the use of primidone, making 
it a first-line treatment in patients with ET.34 Primidone is 
associated with frequent adverse events including sedation, 
nausea, vertigo, and an acute toxic reaction which are usu-
ally more severe soon after treatment initiation.34 A lower 
initial dose and slower titration has not been shown to reduce 
adverse effects compared to an initial dose of 25 mg per day 
and increasing by 25 mg every 4 days.42
Gabapentin is an anticonvulsant with a structure similar 
to gamma-aminobutyric acid (GABA) and is approved as 
adjunctive therapy for partial seizures. One study found 
that gabapentin reduce tremor when used as monotherapy in 
doses of 1,200 mg/day (n = 16), with a 77% improvement in 
tremor as measured by accelerometry at day 15.43 However, 
while gabapentin was found to treat ET in a small number of 
trials as monotherapy, it has not shown efficacy as adjunc-
tive therapy.44,45
Topiramate (Topamax) is an anticonvulsant that has been 
shown to effectively reduce ET.45–48 A large randomized, 
multicenter, double-blinded, placebo-controlled study found 
that patients treated with topiramate had a 29% improvement 
in the FTM rating scale score compared to a 16% improve-
ment in the placebo-treated patients (P , 0.001).48 The aver-
age mean dose of topiramate in the study was 292 mg/day, 
although the between-group difference was significant 
(P , 0.01) at 4 weeks for a topiramate dose of 62 mg/day. 
Side effects were more common in the topiramate group, 
and included paresthesia, weight loss, taste abnormalities, 
memory difficulty, and appetite suppression.
Zonisamide (Zonegran) is an anticonvulsant that may 
have antitremor efficacy, although study results are mixed. 
One controlled study found that zonisamide improved ET 
compared to arotinolol, an antihypertensive agent with mixed 
alpha and beta-blocking action.50 However, at least one addi-
tional study failed to find significant antitremor efficacy from 
zonisamide and a 30% drop-out rate due to adverse events 
including fatigue, diarrhea, and headache.
Levetiracetam (Keppra), a pyrrolidine derivative with 
strong specific binding to cerebellar receptors, failed to show 
significant tremor reduction when tested for several weeks 
compared to placebo in several controlled trials.42,51,52
Pregabalin (Lyrica): the effect of pregabalin on ET is 
unclear. One randomized, double-blinded, placebo-controlled 
trial of 22 patients with ET found a significant reduction in 
tremor amplitude in patients treated with pregabalin group at 
a mean dose of 286 mg/day.53 However, another controlled 
trial of 20 ET patients failed to find improvement in tremor 
rating scale scores in patients taking pregabalin.54
Antibiotics
Isoniazid, an antituberculosis medication, was evaluated 
in a double-blind, randomized, placebo-controlled study of   Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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11 patients with ET.55 At the end of the 4-week treatment 
period, only two patients experienced objective or subjective 
change in their tremor.
Antidepressants
Antidepressants have not been used to treat ET with much 
success. One small study failed to find any reduction in 
clinical ratings of tremor with mirtazapine (Remeron), an 
antagonist of α-2, 5HT2, and 5HT3 receptors.56 Trazodone 
(Desyrel) is a serotoninergic agonist that has been   evaluated 
in two double-blind, randomized, placebo-controlled 
studies.57,58 Both studies failed to find any improvement in 
tremor evaluations based on clinical rating scales.
Antipsychotics
Clozapine (Clozaril) is an atypical neuroleptic with minimal 
extrapyramidal side effects that has been shown to reduce 
tremor by 45%–50% in two controlled studies.59,60 However, 
clozapine use has a 1% risk of agranulocytosis, a serious side 
effect, and its use should be reserved for refractory cases. 
Weekly white cell counts are required for the first 6 months 
of therapy and every other week thereafter. Limited evidence 
is available to determine the utility of olanzapine (Zyprexa) 
and quetiapine (Seroquel) in reducing tremor.
Antivirals
Amantadine (Symmetrel) is an antiviral medication that is used 
to treat PD. A double-blind, cross-over, placebo-controlled trial 
evaluated amantadine (200 mg/day) in 16 patients with ET.21 
After 15 days of treatment tremor measures were not reduced 
compared to baseline in the amantadine group. Over one-third 
of patients experienced increased postural tremor.
Barbituates
Two double-blind, randomized, placebo-controlled crossover 
studies evaluated the effects of phenobarbital, an anticonvul-
sant and sedative, on tremor. One study found a significant 
improvement in accelerometry parameters compared to 
placebo61 but no change in clinical rating scales. The other 
study failed to find a difference compared to placebo.62
Benzodiazepines
Alprazolam (Xanax) has been shown to reduce clinical rat-
ings of tremor in two double-blind, randomized, controlled 
studies.63,64 Although alprazolam has demonstrated effect in 
some patients with ET, it should be used cautiously as it has 
a high potential for abuse. Clonazepam (Klonopin) improved 
tremor compared to baseline in a blinded, controlled study.65 
Another study failed to show any improvement in tremor, 
but had a 60% dropout rate due to side effects.66
Bronchodilators
Studies of theophylline (Theo-dur), a xanthine derivative 
bronchodilator on ET, have found conflicting results. One 
blinded study of a single oral dose of theophylline   evaluated 
changes in tremor over a 24-hour period and found no 
change as measured by volumetric methods (the volume of 
water subjects spilled from a cup held in a flexed position 
for 60 seconds). However, after 3 weeks of treatment with 
  theophylline, tremor was significantly improved using clini-
cal rating scales.67 Another blinded study found a reduction in 
tremor after 4 weeks of treatment compared to placebo.68
Carbonic anhydrase inhibitors
Controlled studies of two carbonic anhydrase inhibitors, 
acetazolamide (Diamox) and methazolamide (Glauctabs, 
Neptazane), failed to find a significant difference in tremor 
evaluations compared to placebo.69,70
Treatment considerations for 
pharmaceutical agents
Both propranolol and primidone have substantial evidence 
supporting their effects in reducing symptoms of ET although 
approximately 30% of patients will not respond to either of 
these agents. As initial therapy, primidone and propranolol 
have shown similar efficacy and the choice of which agent 
to use primarily depends upon a patient’s comorbid condi-
tions and tolerability to either agent. Both medications have 
shown efficacy for at least 1 year,69,70 although there is some 
evidence for a reduction in tremor control over time with both 
medications and a dose increase may be necessary.
Botulinum toxin
Chemodenervation using botulinum toxin A (BTX) has been 
demonstrated to modestly reduce hand tremor in patients 
with ET, but its use is hampered by side effects including 
hand weakness. One randomized, double-blind, placebo-
controlled study evaluated the effects of 50 U and 100 U 
of BTX on limb tremor in 133 patients over a 16-week 
period.73 BTX doses were injected as 15 U into each of the 
flexor carpi radialis and ulnaris and 10 U into each of the 
extensor carpi radialis and ulnaris in one group, and 30 U 
into each of the flexor carpi radialis and ulnaris and 20 U 
into each of the extensor carpi radialis and ulnaris for the Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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second group. Modest benefit was demonstrated by clinical 
ratings of postural and kinetic tremor 6-weeks postinjection 
in both groups.   Subsequent evaluations 12- and 16-weeks 
post-injection did not note tremor reduction compared to 
baseline. Hand weakness was common and occurred in 30% 
of patients who received 50 U of BTX and in 70% of patients 
that received 100 U. One additional controlled study and four 
uncontrolled studies also demonstrated improvement in limb 
tremor with BTX.
Surgical treatment
Surgical procedures may provide treatment of refractory ET. 
Thalamotomy is a stereotactic procedure that creates a lesion 
in the ventral intermediate nucleus (VIM) of the thalamus. 
Studies have typically reported an 80%–90% improvement 
in tremor symptoms compared to baseline.74–76 Side effects 
of thalamotomy include dysarthria, verbal or cognitive defi-
cits, weakness, confusion, somnolence, and paralysis. These 
events have been noted to occur in 14%–47% of patients, and 
usually resolve over time, although hemiparesis and speech 
difficulties persisted in 16% of patients in one study.77 Due 
to the risk of adverse events, bilateral thalamotomies are no 
longer performed to treat ET.
Using placement strategies similar to those used for 
thalamotomy, DBS uses high frequency electrical stimulation 
from an implanted electrode to modify activity in the target 
area, usually the VIM thalamus. The electrodes are connected 
to a pulse generator which is implanted in the chest wall. The 
primary advantage of DBS compared to thalamotomy is that 
simulation parameters such as voltage, pulse frequency, and 
pulse width can be adjusted to optimize tremor control in the 
contralateral limbs. These parameters can be adjusted for con-
tinued management of tremor. Several studies have evaluated 
the effect of DBS on ET and have noted a mean improvement 
in tremor of 60%–90% on clinical ratings.78,79
Adverse events have been reported in approximately 
18% of patients in various VIM DBS studies.34 These events 
were usually related to equipment malfunction or lead mis-
placement. However, other side effects included dysarthria, 
imbalance, paresthesias, weakness, ischemic changes, and 
generalized motor seizures. One study reported a death 
  following the procedure due to intracerebral hemorrhage.80
Surgical treatment of tremor is usually reserved for 
patients who are refractory to pharmacotherapy. Thalamo-
tomy and DBS both suppress tremor and the choice of pro-
cedure primarily depends upon the patient’s circumstances, 
risk of complications as well as the feasibility of ongoing 
programming which is required with DBS.
Conclusion
Despite being one of the most prevalent movement dis-
orders in adults, there are still gaps in the knowledge of 
pathogenesis and effective treatment of ET. Up to 50% of 
patients with ET are misdiagnosed and symptoms of ET can 
overlap with symptoms of other conditions such as PD. It is 
important for physicians to understand this disorder and its 
diagnosis. Many pharmacologic therapies have been tested 
for   effectiveness in treating tremor, but few agents have 
sufficient data available for their use to be widely recom-
mended and only one agent, propranolol, is indicated for the 
treatment of ET. Botulinum toxin and surgical interventions 
are indicated for tremor control but may be associated with 
more severe or persistent side effects than pharmacologic 
therapies. Future controlled studies of treatments for ET 
are warranted.
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